|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1520 News |
|
| «12345678910111213...3031» |
- | FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo, Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion, Enrollment change, Trial primary completion date: Live Versus Inactivated Influenza Vaccine Study in Hutterite Children (clinicaltrials.gov) - Aug 4, 2017
P4, N=4611, Completed, Sponsor: McMaster University
Active, not recruiting --> Completed | N=3800 --> 4611 | Trial primary completion date: Dec 2015 --> Jun 2015
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion, Enrollment change, Trial primary completion date, Adverse events: IVVE:Pilot: Influenza Vaccine To Prevent Adverse Vascular Events:Pilot (clinicaltrials.gov) - Aug 4, 2017
P4, N=107, Completed, Sponsor: McMaster University
Active, not recruiting --> Completed | N=3800 --> 4611 | Trial primary completion date: Dec 2015 --> Jun 2015 Active, not recruiting --> Completed | N=600 --> 107 | Trial primary completion date: Dec 2016 --> Dec 2015
- | Trial completion, Trial primary completion date: Micronutrient Supplementation and Incidence of Common Cold (clinicaltrials.gov) - Aug 1, 2017
P=N/A, N=82, Completed, Sponsor: Green Beat
Active, not recruiting --> Completed | N=600 --> 107 | Trial primary completion date: Dec 2016 --> Dec 2015 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jan 2017
- | amantadine / Generic mfg.
Enrollment change, Trial primary completion date: IRC003: Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications (clinicaltrials.gov) - Jul 11, 2017
P2, N=881, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Jan 2017 N=1200 --> 881 | Trial primary completion date: Sep 2016 --> May 2016
- | Fluzone (influenza vaccine) / Sanofi
Enrollment closed: Immune and Hormone Response to Influenza Vaccine (clinicaltrials.gov) - Jul 11, 2017
P4, N=103, Active, not recruiting, Sponsor: Johns Hopkins Bloomberg School of Public Health
N=1200 --> 881 | Trial primary completion date: Sep 2016 --> May 2016 Recruiting --> Active, not recruiting
- | Trial primary completion date: ResPECT: The Respiratory Protection Effectiveness Clinical Trial (clinicaltrials.gov) - Jun 14, 2017
P=N/A, N=1600, Active, not recruiting, Sponsor: Johns Hopkins University
Recruiting --> Active, not recruiting Trial primary completion date: May 2017 --> Dec 2017
- |||| pimodivir (JNJ-3872) / J&J
Trial completion, Phase classification, Enrollment change, Combination therapy, Monotherapy: Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects (clinicaltrials.gov) - Jun 14, 2017
P2b, N=292, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: May 2017 --> Dec 2017 Recruiting --> Completed | Phase classification: P2 --> P2b | N=500 --> 292
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion, Enrollment change, Trial primary completion date: Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017) (clinicaltrials.gov) - Jun 12, 2017
P4, N=136, Completed, Sponsor: Stanford University
Recruiting --> Completed | Phase classification: P2 --> P2b | N=500 --> 292 Active, not recruiting --> Completed | N=90 --> 136 | Trial primary completion date: Jan 2015 --> Dec 2015
- ||| Trial completion, Trial primary completion date, Pneumococcal vaccines: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (clinicaltrials.gov) - May 31, 2017
P=N/A, N=30000, Completed, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed | N=90 --> 136 | Trial primary completion date: Jan 2015 --> Dec 2015 Enrolling by invitation --> Completed | Trial primary completion date: Dec 2017 --> Jun 2016
- ||||||| oseltamivir / Generic mfg.
Trial completion: A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants. (clinicaltrials.gov) - May 22, 2017
P3, N=233, Completed, Sponsor: Hoffmann-La Roche
Enrolling by invitation --> Completed | Trial primary completion date: Dec 2017 --> Jun 2016 Recruiting --> Completed
- |||| FluMist (influenza vaccine, live, intranasal) / AstraZeneca, Fluzone (influenza vaccine) / Sanofi, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: Control of Epidemic Influenza Through a School-based Influenza Vaccination Program (clinicaltrials.gov) - May 19, 2017
P4, N=29255, Completed, Sponsor: Baylor College of Medicine
Recruiting --> Completed Active, not recruiting --> Completed | N=12000 --> 29255 | Initiation date: Oct 2003 --> Oct 1998 | Trial primary completion date: May 2011 --> Jun 2010
- |||| Fluarix (influenza virus trivalent vaccine) / GSK
Trial primary completion date, IO biomarker: Evaluate Safety & Immunogenicity of GSK Bio's Influenza Vaccine GSK576389A After Repeated Vaccination in Elderly Adults (clinicaltrials.gov) - May 17, 2017
P3, N=1252, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=12000 --> 29255 | Initiation date: Oct 2003 --> Oct 1998 | Trial primary completion date: May 2011 --> Jun 2010 Trial primary completion date: Jun 2008 --> Dec 2007
- Trial primary completion date: Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine (clinicaltrials.gov) - May 15, 2017
P1, N=48, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Jun 2008 --> Dec 2007 Trial primary completion date: Mar 2013 --> Nov 2013
- || Enrollment change, Trial primary completion date, Viral vector: Safety Study of an Oral Vaccine to Prevent Seasonal Influenza (clinicaltrials.gov) - May 12, 2017
P1, N=61, Completed, Sponsor: Vaxart
Trial primary completion date: Mar 2013 --> Nov 2013 N=37 --> 61 | Trial primary completion date: Jan 2014 --> May 2014
- | paracetamol / Generic mfg., ibuprofen / Generic mfg.
Enrollment change, Trial primary completion date: The Benefit and Harm of Fever Suppression by Antipyretics in Influenza (clinicaltrials.gov) - May 3, 2017
P4, N=300, Recruiting, Sponsor: The University of Hong Kong
N=37 --> 61 | Trial primary completion date: Jan 2014 --> May 2014 N=400 --> 300 | Trial primary completion date: Dec 2017 --> Dec 2018
- | Biomarker, Trial completion, Enrollment change: Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE) (clinicaltrials.gov) - May 3, 2017
P=N/A, N=17, Completed, Sponsor: Vanderbilt University
N=400 --> 300 | Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Completed | N=30 --> 17
- | Trial completion, Enrollment change, Trial primary completion date: SKIPP RCT: Efficacy Study of School-located Influenza Vaccination Clinics to Increase Influenza Vaccination Rates in Monroe County, New York (clinicaltrials.gov) - May 1, 2017
P=N/A, N=20461, Completed, Sponsor: University of California, Los Angeles
Recruiting --> Completed | N=30 --> 17 Enrolling by invitation --> Completed | N=39000 --> 20461 | Trial primary completion date: Jan 2017 --> Jul 2015
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion, Trial primary completion date: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Apr 26, 2017
P3, N=310, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Enrolling by invitation --> Completed | N=39000 --> 20461 | Trial primary completion date: Jan 2017 --> Jul 2015 Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- | FluMist (influenza vaccine, live, intranasal) / AstraZeneca, Fluzone (influenza vaccine) / Sanofi, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: B-cell Immunity to Influenza (SLVP017)- Year 1, 2009 (clinicaltrials.gov) - Apr 21, 2017
P4, N=51, Completed, Sponsor: Stanford University
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Active, not recruiting --> Completed
- Enrollment change, Trial withdrawal: Safety and Immunogenicity of a Commercially Available Influenza Vaccine (Formulation 2006/2007) When Administered to Subjects 18 Years of Age or Older (clinicaltrials.gov) - Apr 20, 2017
P2, N=0, Withdrawn, Sponsor: Novartis
Active, not recruiting --> Completed N=125 --> 0 | Suspended --> Withdrawn
- | Enrollment change, Trial primary completion date: MI GIFT: Maternal Immunization: Giving Immunity For Tomorrow (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=166, Completed, Sponsor: University of Utah
N=125 --> 0 | Suspended --> Withdrawn N=300 --> 166 | Trial primary completion date: Nov 2014 --> Dec 2015
- | Zyclara (imiquimod) / Mochida, Viatris, Bausch Health
Enrollment change, Trial termination, Trial primary completion date: CLLIFVAC: Study of Immune Responses to Influenza Vaccination With or Without Imiquimod Application in Untreated CLL Patients (clinicaltrials.gov) - Apr 12, 2017
P2, N=24, Terminated, Sponsor: The Royal Bournemouth Hospital
N=300 --> 166 | Trial primary completion date: Nov 2014 --> Dec 2015 N=102 --> 24 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Recruitment issues
- | Trial completion, Enrollment change: LAIV Immuno: A Phase III/IV Open-label Study of the Immunogenicity and Safety of a Single Dose of a Live Attenuated Influenza Vaccine (LAIV) (FluenzTM) for Each of Three Successive Years in Children na (clinicaltrials.gov) - Apr 6, 2017
P4, N=300, Completed, Sponsor: Public Health England
N=102 --> 24 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2013 --> Dec 2011; Recruitment issues Recruiting --> Completed | N=500 --> 300
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV (clinicaltrials.gov) - Mar 24, 2017
P1/2, N=170, Completed, Sponsor: Mount Sinai Hospital, Canada
Recruiting --> Completed | N=500 --> 300 Active, not recruiting --> Completed
- | Trial completion, Enrollment change, Trial primary completion date: Influenza Immunization of Children in India (clinicaltrials.gov) - Mar 24, 2017
P4, N=18163, Completed, Sponsor: University of Colorado, Denver
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=3600 --> 18163 | Trial primary completion date: Mar 2016 --> May 2014
- oseltamivir / Generic mfg.
Trial primary completion date: A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection (clinicaltrials.gov) - Mar 14, 2017
P1, N=20, Recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Completed | N=3600 --> 18163 | Trial primary completion date: Mar 2016 --> May 2014 Trial primary completion date: Jul 2017 --> May 2018
- | Phase classification: A Study of MHAA4549A in Healthy Volunteers in an Influenza Challenge Model (clinicaltrials.gov) - Mar 9, 2017
P2a, N=101, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Jul 2017 --> May 2018 Phase classification: P2 --> P2a
- | Fludase (oplunofusp) / Ansun Biopharma
Trial initiation date, IO biomarker: Influenza Antiviral DAS-181-F04 in Healthy Adults (clinicaltrials.gov) - Mar 6, 2017
P1, N=9, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Phase classification: P2 --> P2a Initiation date: Aug 2012 --> Aug 2011
- | Vaxelis (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed, inactivated poliovirus, haemophilus b conjugate and hepatitis B vaccine) / Merck (MSD), Sanofi
Trial primary completion date, Combination therapy: Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) (clinicaltrials.gov) - Mar 1, 2017
P3, N=284, Completed, Sponsor: MCM Vaccines B.V.
Initiation date: Aug 2012 --> Aug 2011 Trial primary completion date: Jan 2014 --> Sep 2013
- lenalidomide / Generic mfg.
Trial termination: Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov) - Feb 24, 2017
P2, N=3, Terminated, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Jan 2014 --> Sep 2013 Active, not recruiting --> Terminated; Slow Accrual
- | Ampligen (rintatolimod) / AIM ImmunoTech
Enrollment change, Trial termination, Trial primary completion date: Safety Study of FluMist With and Without Ampligen (clinicaltrials.gov) - Feb 23, 2017
P1/2, N=55, Terminated, Sponsor: Hemispherx Biopharma
Active, not recruiting --> Terminated; Slow Accrual N=72 --> 55 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Sep 2014; The CDC indicated nasal spray flu vaccine should not be used during 2016-2017
- | Fluvirin (inactivated influenza virus vaccine) / CSL Behring, Fluzone (influenza vaccine) / Sanofi
Trial completion, Enrollment change: High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors (clinicaltrials.gov) - Feb 23, 2017
P1, N=28, Completed, Sponsor: Wake Forest University Health Sciences
N=72 --> 55 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2017 --> Sep 2014; The CDC indicated nasal spray flu vaccine should not be used during 2016-2017 Active, not recruiting --> Completed | N=60 --> 28
- oseltamivir / Generic mfg.
Trial primary completion date: Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults (clinicaltrials.gov) - Feb 6, 2017
P=N/A, N=800, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | N=60 --> 28 Trial primary completion date: Jun 2015 --> Jun 2019
- amantadine / Generic mfg.
Trial completion: IRC003: Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications (clinicaltrials.gov) - Feb 1, 2017
P2, N=1200, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Jun 2015 --> Jun 2019 Recruiting --> Completed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial completion: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Feb 1, 2017
P1, N=24, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Jan 24, 2017
P=N/A, N=19, Active, not recruiting, Sponsor: Michael A. Thompson, MD, PhD
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Nov 2017
- || Trial primary completion date, Pneumococcal vaccines: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts (clinicaltrials.gov) - Jan 23, 2017
P=N/A, N=30000, Enrolling by invitation, Sponsor: University of Massachusetts, Worcester
Trial primary completion date: Dec 2016 --> Nov 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Trial completion, Enrollment change: Influenza Vaccine Safety and Effectiveness in Healthcare Providers (clinicaltrials.gov) - Jan 19, 2017
P=N/A, N=1143, Completed, Sponsor: Dalhousie University
Trial primary completion date: Dec 2016 --> Dec 2017 Suspended --> Completed | N=1600 --> 1143
- Trial primary completion date: Two-site Intradermal Influenza Vaccination in Elderly (clinicaltrials.gov) - Nov 28, 2016
P=N/A, N=180, Recruiting, Sponsor: Queen Saovabha Memorial Institute
Suspended --> Completed | N=1600 --> 1143 Trial primary completion date: Dec 2016 --> Dec 2018
- || Fluarix (influenza virus trivalent vaccine) / GSK
Trial primary completion date: A Study to Demonstrate the Efficacy of GSK Biologicals' Influenza Vaccine in Adults (clinicaltrials.gov) - Nov 4, 2016
P4, N=7632, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2016 --> Dec 2018 Trial primary completion date: Dec 2006 --> Jun 2007
- Trial primary completion date: Respiratory Virus Outpatient Study (FLU 002 Plus) (clinicaltrials.gov) - Nov 1, 2016
P=N/A, N=5000, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Dec 2006 --> Jun 2007 Trial primary completion date: Aug 2016 --> Sep 2017
- Enrollment closed, Enrollment change: VAX-002: Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics (clinicaltrials.gov) - Oct 31, 2016
P=N/A, N=33, Active, not recruiting, Sponsor: Emory University
Trial primary completion date: Aug 2016 --> Sep 2017 Recruiting --> Active, not recruiting | N=50 --> 33
- || Trial primary completion date: Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older (clinicaltrials.gov) - Oct 25, 2016
P2, N=1343, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting | N=50 --> 33 Trial primary completion date: Dec 2010 --> Nov 2009
- Trial completion, Enrollment change, Trial initiation date: A Randomized Trial of Vitamin D to Reduce Respiratory Infection (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=1300, Completed, Sponsor: McMaster University
Trial primary completion date: Dec 2010 --> Nov 2009 Recruiting --> Completed | N=300 --> 1300 | Initiation date: Aug 2013 --> Dec 2014
- Trial completion, Enrollment change: Text Messaging Reminders for Influenza Vaccine in Primary Care (clinicaltrials.gov) - Oct 25, 2016
P=N/A, N=156, Completed, Sponsor: London School of Hygiene and Tropical Medicine
Recruiting --> Completed | N=300 --> 1300 | Initiation date: Aug 2013 --> Dec 2014 Active, not recruiting --> Completed | N=60 --> 156
- |||| Fluarix (influenza virus trivalent vaccine) / GSK
Trial primary completion date: Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) (clinicaltrials.gov) - Oct 20, 2016
P3, N=145, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed | N=60 --> 156 Trial primary completion date: Oct 2010 --> Nov 2009
- || Pentacel (diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus and hemophilus b conjugate) / Sanofi
Trial primary completion date: Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants (clinicaltrials.gov) - Oct 20, 2016
P2, N=284, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Oct 2010 --> Nov 2009 Trial primary completion date: Dec 2010 --> Mar 2010
- |||| Fluarix (influenza virus trivalent vaccine) / GSK
Trial primary completion date: Trial to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine GSK2186877A in Adults 65 Year of Age and Older (clinicaltrials.gov) - Oct 20, 2016
P3, N=43695, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2010 --> Mar 2010 Trial primary completion date: Dec 2010 --> Jun 2010
- |||| MenHibrix (GSK 792014) / GSK
Trial completion: Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine (clinicaltrials.gov) - Oct 19, 2016
P2, N=756, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Dec 2010 --> Jun 2010 No longer recruiting --> Completed
- |||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial primary completion date: Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine (clinicaltrials.gov) - Oct 19, 2016
P3, N=793, Completed, Sponsor: GlaxoSmithKline
No longer recruiting --> Completed Trial primary completion date: Oct 2008 --> May 2008